Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Alpha Cognition Inc (ACOG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ACOG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $31.18
1 Year Target Price $31.18
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.77% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.20M USD | Price to earnings Ratio - | 1Y Target Price 31.18 |
Price to earnings Ratio - | 1Y Target Price 31.18 | ||
Volume (30-day avg) 1 | Beta 2.49 | 52 Weeks Range 3.75 - 11.54 | Updated Date 07/22/2025 |
52 Weeks Range 3.75 - 11.54 | Updated Date 07/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28% | Return on Equity (TTM) -79.64% |
Valuation
Trailing PE - | Forward PE 26.88 | Enterprise Value 112563185 | Price to Sales(TTM) 33.52 |
Enterprise Value 112563185 | Price to Sales(TTM) 33.52 | ||
Enterprise Value to Revenue 38.44 | Enterprise Value to EBITDA -1.57 | Shares Outstanding 16019800 | Shares Floating 10409658 |
Shares Outstanding 16019800 | Shares Floating 10409658 | ||
Percent Insiders 1.59 | Percent Institutions 41.77 |
Upturn AI SWOT
Alpha Cognition Inc
Company Overview
History and Background
Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and other forms of dementia. While founded more recently than some of its competitors, it has rapidly advanced its pipeline through clinical trials.
Core Business Areas
- Drug Development: Focuses on developing novel therapies for Alzheimer's disease and other cognitive impairments. This includes preclinical research, clinical trials, and regulatory submissions.
- Intellectual Property: Alpha Cognition Inc. actively seeks to expand and strengthen its intellectual property holdings related to its drug candidates.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure typically includes departments for research, clinical development, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- ALPHA-1062: ALPHA-1062 is a proprietary, reformulated version of an approved cholinesterase inhibitor, designed to improve tolerability and reduce gastrointestinal side effects. Currently in clinical trials for mild to moderate Alzheimer's disease. Market share is not yet available as the product is not approved. Competitors include Aricept (donepezil), Exelon (rivastigmine), and Razadyne (galantamine).
Market Dynamics
Industry Overview
The neurodegenerative disease treatment market is large and growing, driven by an aging population and increasing prevalence of diseases like Alzheimer's. Significant unmet need exists for effective and disease-modifying therapies.
Positioning
Alpha Cognition Inc. is positioned as a company focused on developing innovative therapies with improved safety and efficacy profiles compared to existing treatments. It aims to address the limitations of current Alzheimer's drugs.
Total Addressable Market (TAM)
The global Alzheimer's disease market is estimated to reach billions of dollars. Alpha Cognition Inc. aims to capture a significant portion of this TAM with its pipeline of drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary drug formulation (ALPHA-1062)
- Potential for improved tolerability compared to existing drugs
- Experienced management team
- Focused pipeline on a large market with unmet need
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
- Not yet generating revenue from commercial products
- Small company size
Opportunities
- Successful clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of the pipeline to address other neurodegenerative diseases
- Government funding and support for Alzheimer's research
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies with greater resources
- Regulatory hurdles and delays
- Generic competition if ALPHA-1062 receives marketing approval
Competitors and Market Share
Key Competitors
- PFE
- LLY
- ABBV
Competitive Landscape
Alpha Cognition Inc. faces significant competition from larger pharmaceutical companies with established products and greater financial resources. Its competitive advantage lies in its proprietary formulation and potential for improved tolerability.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in its progress through clinical trials.
Future Projections: Future growth depends on the success of its clinical programs and ability to secure regulatory approvals and commercial partnerships. Analyst estimates not available at this time
Recent Initiatives: Recent initiatives include ongoing clinical trials for ALPHA-1062 and efforts to expand its intellectual property portfolio.
Summary
Alpha Cognition Inc. is a small biopharmaceutical company focused on Alzheimer's disease. The company is still pre-revenue and future growth is uncertain. The main advantage of the company is the proprietary drug formulation but it faces massive competition with minimal resources and will need to secure regulatory approvals and commercial partnerships to grow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Cognition Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2024-11-12 | CEO & Director Mr. Michael E. McFadden B.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.alphacognition.com |
Full time employees - | Website https://www.alphacognition.com | ||
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.